摘要
目的与方法： 观察拓扑替康 (topotecan)对经治晚期卵巢癌患者的疗效和毒性。 67例晚期上皮性卵巢癌患者，年龄 33～ 71岁， 66例曾经手术切除，全部接受过化疗，其中 68.6％患者至少接受过 2种以上方案化疗， 94.0％为含铂类药物治疗失败，采用单药 topotecan 1.25 mg/m2静脉滴注 ,连续 5天，每 21天重复疗程， 85.1％患者用药 2疗程以上。结果： 61例可评价疗效的患者中， CR 6例， PR 7例，总有效率 21.3％。按 ITT分析 67例有效率为 20.9％。中位缓解时间 7.0个月。主要不良反应为血液学毒性， 64.2％患者发生Ⅲ～Ⅳ度白细胞减少， 43.3％患者发生Ⅲ～Ⅳ度血小板减少，中位持续时间 9～ 10天。非血液毒性轻微。结论： Topotecan系晚期卵巢癌经 DDP等药物治疗失败后的有效治疗药物，应在对肿瘤化疗有经验的专科医师监测下使用。
Objective and method: The current study was designed to evaluate the efficacy and toxicity of Topotecan hydrochloride in patients with recurrent advanced ovarian cancer. A total of 67 cases of advanced ovarian cancer patients who received surgical resection and failed previous DDP based chemotherapy were treated with Topotecan 1.25 mg/m2 q.d. i.v. inf.for 5 consecutive days every 3 weeks, 85.1％ of those received 2 or more cycles. Results: Among 61 evaluable cases, 6 CR and 7 PR were achieved with OA response rate of 21.3％ . Among 67 ITT population the response rate was 20.9％ . Median remission period 7.0 months. Main adverse effects were hematologic toxicities, 64.2％ and 43.3％ of cases respectively developed GradeⅢ－Ⅳ leucopenia or thrombocytopemia which lasted for 9－ 10 days. Non hematologic toxicities were mild. Conclusion: Topotecan is effective in advanced ovarian cancer patients who failed DDP based regimes, and careful clinical evaluation before treatment is indicated.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2000年第12期1127-1130,共4页
Chinese Journal of Cancer
